Drugs / BI 905711
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05087992 | Nov 2021 → Oct 2023 | digestive system cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04137289 | Mar 2020 → Jul 2023 | cholangiocarcinoma, pancreatic neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 905711 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05087992 ↗ |
| Action | Activate | “BI 905711 is a novel tetravalent bispecific antibody targeting both TRAILR2 and CDH17 and represents a novel liver-sparing TRAILR2 agonist specifically designed to overcome the...” PMID 33037135 ↗ Oct 2020 |
| Route | Intravenous | “BI 905711 intravenously” NCT04137289 ↗ |
| Target | CDH17 | “BI 905711 is a novel tetravalent bispecific antibody targeting both TRAILR2 and CDH17 and represents a novel liver-sparing TRAILR2 agonist specifically designed to overcome the...” PMID 33037135 ↗ Oct 2020 |